|
AK3L1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.89709997395249E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.52899999997336E-06 |
| Normal-vs-Stage2 |
5.577400E-01 |
| Normal-vs-Stage3 |
4.93900000009262E-07 |
| Normal-vs-Stage4 |
2.17129999535715E-08 |
| Stage1-vs-Stage2 |
4.481800E-02 |
| Stage1-vs-Stage3 |
6.558400E-02 |
| Stage1-vs-Stage4 |
7.317600E-03 |
| Stage2-vs-Stage3 |
3.981200E-03 |
| Stage2-vs-Stage4 |
2.786100E-04 |
| Stage3-vs-Stage4 |
4.227600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.93459725806156E-11 |
| Normal-vs-AfricanAmerican |
1.789240E-01 |
| Normal-vs-Asian |
1.099390E-01 |
| Caucasian-vs-AfricanAmerican |
1.853200E-01 |
| Caucasian-vs-Asian |
2.223800E-03 |
| AfricanAmerican-vs-Asian |
6.818000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.90461999999281E-05 |
| Normal-vs-Female |
6.10789999688777E-08 |
| Male-vs-Female |
7.623800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.05240000053608E-07 |
| Normal-vs-Age(41-60Yrs) |
2.08459999999633E-05 |
| Normal-vs-Age(61-80Yrs) |
7.371100E-04 |
| Normal-vs-Age(81-100Yrs) |
1.143600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.756830E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.310600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.499000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.567200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.838000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.095400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.537880E-02 |
| Classical-VS-Follicular |
6.60915766559356E-13 |
| Classical-VS-Other |
5.988400E-02 |
| Classical-VS-Normal |
3.23951976355374E-12 |
| Tall-VS-Follicular |
2.62120000038557E-07 |
| Tall-VS-Other |
6.028700E-04 |
| Tall-VS-Normal |
3.25410000001636E-06 |
| Follicular-VS-Other |
5.849600E-01 |
| Follicular-VS-Normal |
7.357700E-02 |
| Other-VS-Normal |
8.841400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.196320E-02 |
| Normal-vs-N1 |
1.387790E-04 |
| N0-vs-N1 |
8.118800E-03 |
|
|
